No registrations found.
ID
Source
Health condition
multiple sclerosis, functional magnetic resonance imaging, cognition, functional brain adaptation
multiple sclerose, functionele MRI, cognitie, functionele brein adaptatie
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Improved neuropsychological test performance
- Changed functional MRI/connectivity
- Improved cognitive well-being
Secondary outcome
NA
Study objective
We expect that the disproportionally strong clinical effects of fingolimod in relapsing remitting multiple sclerosis can be explained by enhanced functional adaptation mechanisms of the brain and that enhanced functional adaptation will be sustained over time
Study design
baseline, 6 months and 18 months
Intervention
(functional) magnetic resonance imaging and neuropsychological testing
Inclusion criteria
- Subjects should be between 18 and 65 years of age
- Subjects should meet the safety criteria to undergo MRI examination
- Patients should be diagnosed with RRMS
Exclusion criteria
- Presence or history of psychiatric or neurological disease (for patients: neurological disease other than MS)
- Presence or history of drug abuse
- For patients: relapse or steroid treatment less than four weeks prior to examination
- Insufficient visual acuity and motor skills to perform the fMRI task
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4522 |
| NTR-old | NTR4657 |
| Other | Novartis : CFTY720DNL02T |